{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:00Z","timestamp":1787020740318,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1154-x","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T10:02:27Z","timestamp":1564653747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-3408","authenticated-orcid":false,"given":"V.","family":"Vanhoorne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Van Tongelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Boussery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wynendaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"De Spiegeleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vervaet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"1154_CR1","unstructured":"Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official Journal of the European Union 2009\/C 151\/02 of 8 June 2009. \n                    https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF\n                    \n                  ."},{"key":"1154_CR2","unstructured":"Inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products - Final state of Play 2015. \n                    https:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/orphanmp\/doc\/orphan_inv_report_20160126.pdf\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrd3445","volume":"10","author":"The committee for orphan medicinal products and the European medicines agency scientific secretariat","year":"2011","unstructured":"The committee for orphan medicinal products and the European medicines agency scientific secretariat. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10:341\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"1154_CR4","first-page":"109","volume":"4","author":"A Denis","year":"2009","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Weesgeneesmiddelen: een Belgische en Europese analyse. Farmaceutisch tijdschrift Voor Belgi\u00eb. 2009;4:109\u201315.","journal-title":"Farmaceutisch tijdschrift Voor Belgi\u00eb"},{"key":"1154_CR5","unstructured":"Communication from the commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions, on rare diseases: Europe\u2019s challenges. \n                    https:\/\/publications.europa.eu\/en\/publication-detail\/-\/publication\/c8a042d8-ffb9-4b01-9c91-c1497a2b3fd7\/language-en\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR6","unstructured":"EMA. Orphan Medicines Figures 2000\u20132017. \n                    https:\/\/www.ema.europa.eu\/documents\/other\/orphan-medicines-figures-2000-2017_en.pdf\n                    \n                  . Accessed 31 Dec 2018."},{"key":"1154_CR7","unstructured":"Fonds zeldzame ziekten en weesgeneesmiddelen. Aanbevelingen en voorstellen tot maatregelen voor een Belgisch plan voor zeldzame ziekten. \n                    https:\/\/www.zorg-en-gezondheid.be\/sites\/default\/files\/atoms\/files\/Plan_ZZ_aanbevelingen_KBS.pdf\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR8","unstructured":"Directie Farmaceutisch Beleid \u2013 Dienst voor Geneeskundige Verzorging RIZIV. Monitoring of reimbursement significant expenses report MORSE 2018. \n                    https:\/\/www.riziv.fgov.be\/SiteCollectionDocuments\/morse-rapport-2016.pdf\n                    \n                  . Accessed 31 Dec 2018."},{"key":"1154_CR9","unstructured":"STAMP Commission Expert Group. Off-label use of medicinal products, report of 14 March 2017. \n                    https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/committee\/stamp\/stamp6_off_label_use_background.pdf\n                    \n                  . Accessed 11 July 2018."},{"key":"1154_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0741-y","volume":"13","author":"M Dooms","year":"2018","unstructured":"Dooms M, Carvalho M. Compounded medication for patients with rare diseases. Orphanet J Rare Dis. 2018;13:1\u20138.","journal-title":"Orphanet J Rare Dis"},{"key":"1154_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.12006","volume":"38","author":"M Dooms","year":"2013","unstructured":"Dooms M, Pinc\u00e9 H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther. 2013;38:1\u20132.","journal-title":"J Clin Pharm Ther"},{"key":"1154_CR12","first-page":"9","volume":"1","author":"M Dooms","year":"2009","unstructured":"Dooms M. Weesgeneesmiddelen. Farmaceutisch Tijdschrift Voor Belgi\u00eb. 2009;1:9\u201313.","journal-title":"Farmaceutisch Tijdschrift Voor Belgi\u00eb"},{"key":"1154_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/phrs.1999.0644","volume":"42","author":"P Minghetti","year":"2000","unstructured":"Minghetti P, Giudici EM, Montanari L. A proposal to improve the supply of orphan drugs. Pharmacol Res. 2000;42:33\u20137.","journal-title":"Pharmacol Res"},{"key":"1154_CR14","first-page":"40","volume":"17","author":"E Peila","year":"2011","unstructured":"Peila E, Fogliano MR, Crosasso P, Mosso B, Chiappetta MR, Viterbo ML, Mazengo M, Stecca S, Baldovino S, Roccatello D. Extemporaneous orphan drugs and preparations for rare diseases: organization and management of an inter-regional network. Eur J Hosp Pharm. 2011;17:40\u20135.","journal-title":"Eur J Hosp Pharm"},{"key":"1154_CR15","unstructured":"The portal for rare diseases and orphan drugs. \n                    http:\/\/www.orpha.net\/consor\/cgi-bin\/Disease.php?lng=EN\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR16","unstructured":"U.S. Food and drug administration Search orphan drug designations and approvals. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/\n                    \n                  . Accessed 12 June 2019."},{"key":"1154_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-7-32","volume":"7","author":"J H\u00e4berle","year":"2012","unstructured":"H\u00e4berle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Sanjurjo Crespo P, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32\u201362.","journal-title":"Orphanet J Rare Dis"},{"key":"1154_CR18","unstructured":"Matern D, Rinaldo P. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. In: Adam MP, editor. Gene Reviews. Seattle; 2015. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1424\/\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR19","unstructured":"El-Hattab AW. Systemic Primary Carnitine Deficiency. In: Adam MP, editor. Gene Reviews. Seattle; 2016. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK84551\/\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR20","unstructured":"Van Hove J, Coughlin C, Scharer G. Glycine Encephalopathy. In: Adam MP, editor. Gene Reviews. Seattle; 2013. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1357\/\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR21","unstructured":"Federico A, Dotti MT, Gallus GN. Cerebrotendinous Xanthomatosis. In: Adam MP, editor. Gene Reviews. Seattle; 2016. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1409\/\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-014-0179-4","volume":"9","author":"S Nie","year":"2014","unstructured":"Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis and management. Orphanet J Rare Dis. 2014;9:1\u201311.","journal-title":"Orphanet J Rare Dis"},{"key":"1154_CR23","unstructured":"WHO. Essential Medicines and health products information portal. \n                    http:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh2922e\/2.5.4.html#Jh2922e.2.5.4\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR24","unstructured":"WHO. Essential Medicines and health products information portal. \n                    http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js2215e\/9.21.html#Js2215e.9.21\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418\u201325.","journal-title":"Malar J"},{"key":"1154_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351\u201363.","journal-title":"Malar J"},{"key":"1154_CR27","doi-asserted-by":"publisher","first-page":"A72","DOI":"10.1136\/ejhpharm-2013-000276.202","volume":"20","author":"C Serrano","year":"2013","unstructured":"Serrano C, Joret P, Siorat V, Vaconsin P, Abarou T, Storme T. Development of Pyridoxal-5-phosphate hard capsules for paediatric use. Eur J Hosp Pharm. 2013;20:A72.","journal-title":"Eur J Hosp Pharm"},{"key":"1154_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10545-006-0508-4","volume":"30","author":"GF Hoffmann","year":"2007","unstructured":"Hoffmann GF, Schmitt B, Windfuhr M, Wagner N, Strehl H, Gagci S, Franz AR, Mills PB, Clayton PT, Baumgartner MR, Steinmann B, Bast T, Wolf NI, Zschocke J. Pyridoxal-5-phosphate may be curative in early-onset epileptic encephalopathy. J Inherited Metab Dis. 2007;30:96\u20139.","journal-title":"J Inherited Metab Dis"},{"key":"1154_CR29","unstructured":"BCFI. \n                    http:\/\/www.bcfi.be\/nl\/articles\/891?folia=839&matches=\n                    \n                  . Accessed 26 Mar 2019."},{"key":"1154_CR30","unstructured":"European Pharmacopeia, Monograph 0806 on L-arginine. 2015."},{"key":"1154_CR31","unstructured":"European Pharmacopeia, Monograph 1189 on chenodesoxycholic acid."},{"key":"1154_CR32","unstructured":"European Pharmacopeia, Monograph 2034 on substances for pharmaceutical use."},{"key":"1154_CR33","unstructured":"European Pharmacopeia, Monograph 2.9.6 on uniformity of mass of single dose preparations."},{"key":"1154_CR34","unstructured":"European Pharmacopeia, Monograph 1603 on bitter-orange epicarp and mesocarp."},{"key":"1154_CR35","unstructured":"European Pharmacopeia, Monograph 1604 on bitter-orange epicarp and mesocarp tincture."},{"key":"1154_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.fct.2005.01.020","volume":"43","author":"MG Soni","year":"2005","unstructured":"Soni MG, Carabin IG, Burdock GA. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food Chem Toxicol. 2005;43:985\u20131015.","journal-title":"Food Chem Toxicol"},{"key":"1154_CR37","first-page":"34","volume":"4","author":"M Dooms","year":"2009","unstructured":"Dooms M. Weesgeneesmiddelen: zes spijtige misverstanden en \u00e9\u00e9n harde waarheid. Antwerps Farmaceutisch Tijdschrift. 2009;4:34\u20136.","journal-title":"Antwerps Farmaceutisch Tijdschrift"},{"key":"1154_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2165\/11601640-000000000-00000","volume":"27","author":"S Simoens","year":"2011","unstructured":"Simoens S, Cassiman D, Picavet E, Dooms M. Are some orphan drugs for rare diseases too expensive? Drugs Ther Perspect. 2011;27:24\u20136.","journal-title":"Drugs Ther Perspect"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1154-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T19:31:52Z","timestamp":1596137512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1154-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1154-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"29 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}